Biocon’s subsidiary – Biocon Sdn Bhd & Duopharma Marketing Sdn Bhd boosted the supply of locally produced Insugen (recombinant human insulin)
Bengaluru, India and Johor, Malaysia, April 26, 2022 – Biocon Biologics Limited(BBL), a subsidiary of Biocon Ltd., today announced that its subsidiary Biocon Sdn. Bhd. in Malaysia has been awarded a three-year contract, valued at USD 90 million* (MYR 375 million), for its recombin...
Biocon Sdn. Bhd has set up state of the art integrated manufacturing facility for insulin active pharmaceutical ingredients and insulin drug formulation in Johor, Malaysia. During the year, the Company has invested USD 91,800 in Biocon Sdn. Bhd. towards Non-cumulative redeemable convertible ...